Carpal Tunnel Syndrome Medical Services in China

Carpal tunnel syndrome (CTS) is a common peripheral nerve compression disorder caused by increased pressure on the median nerve as it passes through the carpal tunnel—a narrow, rigid passageway in the wrist formed by carpal bones and the transverse carpal ligament. Symptoms typically include numbness, tingling, burning pain, and weakness in the thumb, index, middle, and radial half of the ring finger, often worsening at night or with repetitive hand use. Electrodiagnostic studies—nerve conduction velocity (NCV) and electromyography (EMG)—remain the gold standard for objective diagnosis and severity grading. Conservative management includes wrist splinting, corticosteroid injections, and activity modification; however, surgical decompression—either open or endoscopic carpal tunnel release—is indicated for moderate-to-severe cases unresponsive to nonoperative treatment or presenting with thenar muscle atrophy or persistent neurologic deficits.

China offers distinct advantages for CTS treatment: its orthopedic and hand surgery specialists possess extensive experience managing complex nerve entrapment cases, supported by state-of-the-art intraoperative neuromonitoring, high-resolution ultrasound for dynamic assessment, and minimally invasive endoscopic techniques that reduce postoperative morbidity. Leading tertiary hospitals report >95% symptom resolution rates at 12-month follow-up, with low complication incidence (<2%). Treatment costs—including diagnostics, surgery, and rehabilitation—are typically 40–60% lower than in the US, UK, or Germany, without compromising clinical standards or accreditation (many centers hold JCI or ISO certification). As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying surgeon credentials, coordinating appointments at vetted hospitals, providing itemized, transparent pricing in advance, arranging translation, accommodation, and postoperative follow-up—all tailored to individual clinical and logistical needs.

Treatment Options & Itemized Cost Breakdown: Carpal Tunnel Syndrome (Orthopedics)

Non-Surgical / Conservative Management

*Indicated for mild-to-moderate symptoms <6 months duration, no thenar atrophy or persistent sensory loss.*

• •Wrist Splinting (Night + Activity): $25–$45 (Tier 1: basic thermoplastic; Tier 2: custom-fitted, adjustable)
• •NSAIDs (e.g., celecoxib 200 mg/day × 2 weeks): $8–$12 (generic oral course)
• •Corticosteroid Injection (ultrasound-guided, single dose): $180–$260

• •Physical Therapy (8 sessions, nerve gliding + ergonomic training): $320–$480 ($40–$60/session)
• •Pre-treatment Workup: Nerve conduction study (NCS)/EMG: $190–$270; wrist X-ray (AP/lateral): $45

Surgical / Interventional Options

*Indicated for severe symptoms (>6 months), motor weakness, thenar atrophy, or failed conservative therapy.*

• •Open Carpal Tunnel Release (OCTR): $2,100–$2,900

• •Endoscopic Carpal Tunnel Release (ECTR): $2,600–$3,400

• •Preoperative Workup: CBC ($12), PT/INR ($15), ECG ($22), chest X-ray ($38), NCS/EMG (if not recent): $190–$270

Special / Complex Condition Management

• •Recurrent CTS (post-surgery): Revision OCTR with intraoperative ultrasound + neurolysis: $3,300–$4,100
• •CTS with Diabetes or Uremia: Requires extended pre-op metabolic optimization (HbA1c testing $28, eGFR panel $32) + perioperative glucose monitoring ($110); total surgical cost adds $220–$350
• •Bilateral Simultaneous Surgery: 15% discount on second-side fees; total $4,400–$5,800 (vs. sequential: $4,700–$6,300)

Quick Selection Guide

• •<45 years, mild symptoms, budget <$200: Start with splinting + NSAIDs ($33–$57 total)
• •45–65 years, moderate symptoms, comorbid diabetes: Ultrasound-guided injection + NCS ($370–$530); avoid surgery until glycemic control (HbA1c <7.5%)
• •>65 years, thenar atrophy or nocturnal awakening × >4x/week: Proceed directly to OCTR ($2,100–$2,900); ECTR not recommended due to higher learning-curve complication risk in elderly
• •Bilateral, working-age patient, urgent functional recovery: Bilateral simultaneous OCTR ($4,400–$5,800) minimizes lost workdays vs. staged procedures
• •Failed prior injection, persistent weakness: OCTR is first-line surgical choice—no cost advantage to ECTR in real-world Grade 3A settings due to higher instrument costs and longer setup time